Checkpoint Therapeutics Stock Forecast, Price & News

+0.15 (+6.36 %)
(As of 05/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.14 million shs
Average Volume1.30 million shs
Market Capitalization$188.78 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CKPT
Year FoundedN/A

Sales & Book Value

Annual Sales$1.71 million
Book Value$0.34 per share


Net Income$-24,710,000.00
Net Margins-2,032.05%




Market Cap$188.78 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable


See More Headlines
Checkpoint Therapeutics logo

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.


Overall MarketRank

1.22 out of 5 stars

Medical Sector

905th out of 2,042 stocks

Pharmaceutical Preparations Industry

424th out of 770 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

Is Checkpoint Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Checkpoint Therapeutics stock.
View analyst ratings for Checkpoint Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Checkpoint Therapeutics?

Wall Street analysts have given Checkpoint Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Checkpoint Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Checkpoint Therapeutics

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Checkpoint Therapeutics had a negative net margin of 2,032.05% and a negative trailing twelve-month return on equity of 100.54%.
View Checkpoint Therapeutics' earnings history

How has Checkpoint Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CKPT stock has increased by 88.7% and is now trading at $2.51.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CKPT?

3 brokerages have issued 1 year price targets for Checkpoint Therapeutics' shares. Their forecasts range from $16.00 to $20.00. On average, they anticipate Checkpoint Therapeutics' share price to reach $17.67 in the next year. This suggests a possible upside of 603.9% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:
  • Mr. James F. Oliviero III, C.F.A., CFA, CEO, Pres & Director (Age 45, Pay $732k)
  • Mr. William Garrett Gray, Chief Financial Officer (Age 34, Pay $249.85k)

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), (KDMN) and Rigel Pharmaceuticals (RIGL).

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.71%), Spotlight Asset Group Inc. (0.87%) and Occidental Asset Management LLC (0.04%). Company insiders that own Checkpoint Therapeutics stock include James F Oliviero III, Lindsay A Md Rosenwald and William Garrett Gray.
View institutional ownership trends for Checkpoint Therapeutics

Which major investors are buying Checkpoint Therapeutics stock?

CKPT stock was purchased by a variety of institutional investors in the last quarter, including Spotlight Asset Group Inc., BlackRock Inc., and Occidental Asset Management LLC.
View insider buying and selling activity for Checkpoint Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $2.51.

How much money does Checkpoint Therapeutics make?

Checkpoint Therapeutics has a market capitalization of $188.78 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Checkpoint Therapeutics have?

Checkpoint Therapeutics employs 10 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is

Where are Checkpoint Therapeutics' headquarters?

Checkpoint Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 5/9/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.